You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 8, 2024

Claims for Patent: 6,858,608


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,858,608
Title: Chemical derivatives and their application as antitelomerase agents
Abstract:The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
Inventor(s): Mailliet; Patrick (Fontenay Sous Bois, FR), Riou; Jean-Fran.cedilla.ois (Reims, FR), Alasia; Marcel (Choisy Le Roi, FR), Caulfield; Thomas (Paris, FR), Doerflinger; Gilles (Les Ulis, FR), Mergny; Jean-Louis (Villejuif, FR), Laoui; Abdelazize (Bridgewater, NJ), Petitgenet; Odile (Paris, FR), Renou; Emmanuelle (Paris, FR)
Assignee: Aventis Pharma S.A. (Antony, FR)
Application Number:10/040,370
Patent Claims:1. A compound which binds the G-quadruplex structure of a telomere comprising the following general formula:

in which 1) the nitrogen-containing aromatic ring represents: a) a quinoline optionally substituted with at least i) a group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a C1-C4 alkyl radical or ii) a group ORa in which Ra is as defined above b) a quinoline possessing a nitrogen atom in quaternary form c) a benzamidine or d) a pyridine, attached at the 4-position, 2) R.sub.3 and R'.sub.3, which are identical or different, represent independently of each other, hydrogen or a C1-C4 alkyl radical, 3) the distribution agent represents: a triazine group, a triazine group substituted with (i) an alkyl radical having 1 to 4 carbon atoms, (ii) a thio radical, (iii) an hydroxy radical, or (iv) an amino radical, wherein the thiol, hydroxy or amino radicals are unsubstituted or substituted with one or more short-chain alkyl groups containing 1 to 4 carbon atoms and wherein the alkyl is unsubstituted or substituted with a halogen atom or

or a salt thereof.

2. The compound according to claim 1, wherein the distribution agent is a triazine group.

3. The compound according to claim 1, wherein the nonaromatic hydrocarbon chain is chosen from among i) alkyl (C1-C4), alkenyl (C2-C4), wherein the alkyl and alkenyl are linear or branched, ii) cycloalkyl (C3-C18) iii) cycloalkenyl (C3-C18) iv) heterocycloalkyl (C3-C18) and v) heterocycloalkyl (C3-C18) including the nitrogen atom of the NR'.sub.3 group.

4. The compounds according to claim 3, wherein the nonaromatic hydrocarbon chain is unsubstituted or substituted with one or more atoms or radicals chosen from among halogen atoms, hydroxyl, aryl, heteroaryl, alkyloxy, aryloxy, thiol, alkylthio, arylthio, amino, alkylamino, arylamino, dialkylamino, diarylamino, amidino, guanidino, alkylcarbonylamino, arylcarbonylamino, carboxyl, alkyloxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonyl, arylcarbonyl, cyano, trifluoromethyl, and combinations thereof.

5. The compounds according to claim 4, wherein the alkyl chains comprise substituents having a hydrocarbon chain containing 1 to 4 carbon atoms, and the aryl groups comprise substituents having a hydrocarbon chain containing 5 to 18 carbon atoms.

6. The compounds according to claim 3, wherein the alkyl chains contain 2 to 3 carbon atoms, and the heterocycloalkyl or cycloalkyl chains contain 5 to 7 carbon atoms.

7. The compounds according to claim 1, comprising formula (I) below: ##STR37##

in which: 1) A represents: a) an amino group of formula NR1R2 in which R1 and R2, which are identical or different, represent hydrogen or a straight or branched alkyl group containing 1 to 4 carbon atoms or b) a group OR1 or SR1 in which R1 has the same meaning as above or c) an alkyl group containing 1 to 4 carbon atoms or a trifluoromethyl group or d) a hydrogen atom or e) a halogen atom chosen from fluorine, chlorine, bromine and iodine, 2) R.sub.3 and R'.sub.3, which are identical or different, represent independently of each other hydrogen or a C1-C4 alkyl group, 3) Ar.sub.1 represents a nitrogen-containing aromatic ring representing: a) a quinoline, either unsubstituted or substituted with at least i) a group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a C1-C4 alkyl radical or ii) a group ORa in which Ra is as defined above b) a quinoline possessing a nitrogen atom in quaternary for c) a benzamidine or d) a pyridine attached at the 4-position or fused with an aryl or heteroaryl group e) a pyridine attached at the 4-position or fused with an aryl or heteroaryl group substituted with a C1-C4 alkyl group, 4) Alk represents a nonaromatic unsubstituted or substituted hydrocarbon chain chosen from among alkyl (C1-C4), alkenyl (C2-C4), wherein the alkyl and alkenyl chain are linear or branched, cycloalkyl (C3-C18), cycloalkenyl (C3-C18) heterocycloalkyl (C3-C18), and heterocycloalkyl (C3-C18) including the nitrogen atom of the NR'3 group.

or a salt thereof.

8. The compound according to claim 7, wherein the nonaromatic hydrocarbon chain is unsubstituted or substituted with one or more atoms or radicals chosen from among halogen atoms, hydroxyl, aryl, heteroaryl, alkyloxy, aryloxy, thiol, alkylthio, arylthio, amino, alkylamino, arylamino, dialkylamino, diarylamino, amidino, guanidino, alkylcarbonylamino, arylcarbonylamino, carboxyl, alkyloxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonyl or arylcarbonyl, cyano, trifluoromethyl, and combinations thereof.

9. The compounds according to claim 7, wherein Ar.sub.1 represents 4-amino- or 4-methylamino- or 4-dimethylamino-quinolyl or quinolinium, wherein the quinolinium nucleus is unsubstituted or substituted with a methyl group.

10. The compounds according to claim 7, wherein group A represents a thiomethyl, amino, alkylamino or dialkylamino, in which the alkyl groups in the radicals possess 1 to 4 carbon atoms.

11. The compounds according to claim 7, wherein A represents a methylthio group.

12. The compounds according to claim 7, wherein Alk represents an alkyl containing 2 to 3 linear or branched carbon atoms, wherein the alkyl is substituted with i) an amino, alkylamino, arylamino, dialkylamino, diarylamino, or combination thereof ii) an alkenyl unit containing 2 to 3 carbon atoms, which is substituted with an amino, alkylamino arylamino, dialkylamino, diarylamino, heterocyclyl containing from 4 to 7 carbon atoms, or a combination thereof.

13. The compounds according to claim 7, wherein Alk represents a 2-(dialkylamino)ethyl, 3-(dialkylamino)propyl, 2-(N-alkyl-N-arylamino)ethyl, or 3-(N-alkyl-N-arylamino)propyl, in which the alkyl groups contain 1 to 4 carbon atoms and the aryl groups contain 5 to 18 carbon atoms.

14. The compounds according to claim 7, wherein Alk represents 2-(N-m-tolyl-N-ethylamino)ethyl.

15. A compounds corresponding to the following formula (I): ##STR38##

in which: 1) A represents a) an amino group of formula NR1R2 in which R1 and R2, which are identical or different, represent hydrogen or a straight or branched alkyl group containing 1 to 4 carbon atoms or b) a group OR1 or SR1 in which R1 has the same meaning as above c) an alkyl group containing 1 to 4 carbon atoms or a trifluoromethyl group d) a hydrogen atom or e) a halogen atom chosen from fluorine, chlorine, bromine and iodine, 2) R.sub.3 and R'.sub.3, which are identical or different, represent independently of each other hydrogen or a C1-C4 alkyl group, 3) Ar.sub.1 represents a nitrogen-containing aromatic ring representing: a) a quinoline, either unsubstituted or substituted with at least i) a group N(Ra)(Rb) in which Ra and Rb, which are identical or different, represent hydrogen or a C1-C4 alkyl radical or ii) a group ORa in which Ra is as defined above b) a quinoline possessing a nitrogen atom in quaternary form or c) a benzamidine or d) a pyridine attached at the 4-position or fused with an aryl or heteroaryl group or e) a pyridine attached at the 4-position or fused with an aryl or heteroaryl group substituted with a C1-C4 alkyl group, 4) alk represents a nonaromatic unsubstituted or substituted hydrocarbon chain chosen from among alkyl (C1-C4), alkenyl (C2-C4), wherein the alkyl and alkenyl chain are linear or branched, cycloalkyl (C3-C18), cycloalkenyl (C3-C18), heterocycloalkyl (C3-C18), and heterocycloalkyl (C3-C18) including the nitrogen atom of the NR'3 group,

or a salt thereof.

16. The compounds according to claim 15, wherein the nonaromatic hydrocarbon chain is unsubstituted or substituted with one or more atoms or radicals chosen from among halogen atoms, hydroxyl, aryl, heteroaryl, alkyloxy, aryloxy, thiol, alkylthio, arylthio, amino, alkylamino, arylamino, dialkylamino, diarylamino, amidino, guanidino, alkylcarbonylamino, arylcarbonylamino, carboxyl, alkyloxycarbonyl, aryloxycarbonyl, aminocarbonyl, alkylaminocarbonyl, arylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonyl, arylcarbonyl, cyano, trifluoromethyl, and combinations thereof.

17. The compounds according to claim 15, wherein Ar.sub.1 represents 4-amino- or 4-methylamino- or 4-dimethylamino-quinolyl or quinolinium, wherein the quinolinium nucleus is unsubstituted or substituted with a methyl group.

18. The compounds according to claim 15, wherein group A represents a thiomethyl, amino, alkylamino or dialkylamino, in which the alkyl groups in the radicals possess 1 to 4 carbon atoms.

19. The compounds according to claim 15, wherein R1 and R2 represent hydrogen.

20. The compound according to claim 18, wherein A represents a methylthio group.

21. The compound according to claim 15, wherein alk represents i) an alkyl containing 2 to 3 linear or branched carbon atoms which is substituted with an amino, alkylamino, arylamino, dialkylamino, diarylamino, or combination thereof, ii) an alkenyl unit containing 2 to 3 carbon atoms, which is substituted with an amino, alkylamino, arylamino, dialkylamino, diarylamino, or combination thereof, or iii) a heterocyclyl containing from 4 to 7 carbon atoms.

22. The compound according to claim 15, wherein alk represents 2-(dialkylamino)ethyl, 3-(dialkylamino)propyl, 2-(N-alkyl-N-arylamino)ethyl or 3-(N-alkyl-N-arylamino)propyl, in which the alkyl groups contain 1 to 4 carbon atoms and the aryl groups contain 5 to 18 carbon atoms.

23. The compound according to claim 21, characterized in that alk represents a 2-(N-m-tolyl-N-ethylamino)ethyl.

24. A therapeutic composition comprising a compound according to claim 1 and one or more anticancer compounds.

25. The composition according to claim 24, wherein the one or more anticancer compounds are chosen from among alkylating agents, platinum derivatives, antibiotic agents, antimicrotubule agents, anthracyclines, group I and II topoisomerases, fluoropyrimidines, cytidine analogs, adenosine analogs, L-asparaginase, hydroxyurea, trans-retinoic acid, suramine, irinotecan, topotecan, dexrazoxane, amifostine, herceptin, estrogenic hormones, and androgenic hormones.

26. A method of using the composition of claim 25, wherein the individual compounds are administered in a therapeutically effective amount to a patient simultaneously separately or sequentially.

27. A method of inhibiting telomerase activity, comprising administering a therapeutically effective amount of one or more compounds of claim 1 to a patient, wherein the level of telomerase activity in the patient following the administration is reduced relative to the level of telomerase activity existing prior to the administration.

28. A method of treating a cancer, comprising administering a therapeutically effective amount of one or more compounds of claim 1 to a patient in need of such a treatment, wherein the level of telomerase activity following the administration is reduced relative to the level of telomerase activity existing prior to the administration.

29. A pharmaceutical composition comprising one or more compounds of claim 1, and a pharmaceutically acceptable carrier.

30. A therapeutic combination consisting of the administration of one or more compounds according to claim 1 and the administration of radiation.

Details for Patent 6,858,608

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 ⤷  Try a Trial 2021-01-09
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2021-01-09
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2021-01-09
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.